-
Identification of novel SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors: From in silico screening to experimentally validated inhibitory activity
- Back
Metadata
Document Title
Identification of novel SARS-CoV-2 RNA dependent RNA polymerase (RdRp) inhibitors: From in silico screening to experimentally validated inhibitory activity
Author
Uengwetwanit T, Chutiwitoonchai N, Wichapong K, Karoonuthaisiri N
Name from Authors Collection
Affiliations
National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); Maastricht University; Queens University Belfast
Type
Article
Source Title
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
ISSN
2001-0370
Year
2022
Volume
20
Page
882-890
Open Access
Green Published, gold
Publisher
ELSEVIER
DOI
10.1016/j.csbj.2022.02.001
Format
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has posed a serious threat to global health and the economy for over two years, prompting the need for development of antiviral inhibitors. Due to its vital role in viral replication, RNA-dependent RNA polymerase (RdRp) is a promising therapeutic target. Herein, we analyzed amino acid sequence conservation of RdRp across coronaviruses. The conserved amino acids at the catalytic binding site served as the ligand-contacting residues for in silico screening to elucidate possible resistant mutation. Molecular docking was employed to screen inhibitors of SARS-CoV-2 from the ZINC ChemDiv database. The top-ranked compounds selected from GOLD docking were further investigated for binding modes at the conserved residues of RdRp, and ten compounds were selected for experimental validation. Of which, three compounds exhibited promising antiviral activity. The most promising candidate showed a half-maximal effective concentration (EC50) of 5.04 mu M. Molecular dynamics simulations, binding free-energy calculation and hydrogen bond analysis were performed to elucidate the critical interactions providing a foundation for developing lead compounds effective against SARS-CoV-2. (C) 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.
Keyword
coronavirus | Drug discovery | Inhibitor | molecular docking | SARS-CoV-2 | Virtual screening
Industrial Classification
Knowledge Taxonomy Level 1
Knowledge Taxonomy Level 2
Funding Sponsor
National Center for Genetic Engineering and Biotechnology (BIOTEC), Thailand [P-2051635]
License
CC BY-NC-ND
Rights
Authors
Publication Source
WOS